Avantra Biosciences announced this week the first shipments of its Q400 Biomarker Workstation and Angio Qx BioChip immunoassay for the study of tumor vascularization.
The shipments mark the culmination of the long journey back to the market for the platform. Originally developed by defunct biotech firm Decision Biomarkers, the platform was purchased in bankruptcy court with the rest of Decision's assets in December 2009 by Courtagen Capital Group, which launched Avantra in July of last year.
At that time, Elizabeth Holland, spokesperson for Courtagen and Avantra, told ProteoMonitor that the company planned to begin selling the workstation in early 2011 (PM 7/23/2010). In August of last year Avantra raised $7 million in equity funding (GWDN 08/18/2010).
Currently a research-use-only device, the Q400 consists of an assay-processing and fluorescence-imaging platform and disposable biochips that contain all the reagents required for performing multiplex biomarker assays. The company plans to seek regulatory approval for the platform and its assays in the future.
The shipment of the Q400 and the Angio Qx assay are "the first milestone in Avantra's strategy to develop a suite of oncology focused multiplex biomarker panels," Avantra CEO Brian McKernan said in statement.